NEO-102: Interim Phase I/IIa data

Interim data from 9 evaluable patients with refractory metastatic pancreatic and colorectal cancer in an open-label, U.S. Phase I/IIa trial showed that IV NEO-102 led to 5 cases of stable disease. Of ...